Naci TOPALOĞLU, Gülsün MEMİ, Tuncay KANER, Mustafa DENİZ, Önder ŞAHİN, Mustafa GÜVEN, Murat ÇOŞAR

Does Glp-2 have a protective effect on cerebral ischemia/reperfusion model?

Background/aim: To investigate the neuroprotective effects of glucagon-like peptide 2 (Glp-2), which increases cerebral blood flow, on the hippocampal complex after cerebral ischemia/reperfusion (I/R) injury in rats. Materials and methods: Animals were randomized into 4 groups: sham, I/R + 0.9% NaCl, I/R + pre-Glp-2, and I/R + post-Glp-2. Cerebral ischemia was performed via the occlusion of the bilateral internal carotid artery for 40 min and continued with a reperfusion process. At the end of 6 h of reperfusion, animals were decapitated in all groups and brain tissues were removed. Malondialdehyde (MDA) and natural intracellular antioxidant glutathione (GSH) levels and myeloperoxidase (MPO) activities were measured in the left hippocampal tissue. The right hippocampal tissues of all group members were taken for histopathologic study. Results: MDA levels and MPO activities increased from Group I to Group II and decreased from Group II to Groups III and IV. On the other hand, GSH levels were not significantly different among the groups. The number of apoptotic hippocampal tissue cells increased from Group I to Group II and decreased from Group II to Groups III and IV. Conclusion: Our preliminary study revealed that Glp-2 treatment may decrease oxidative damage from I/R in cerebral tissue.

Anahtar Kelimeler:

Reperfusion injury, glucagon-like peptide 2, neuroprotective effect, rats

Does Glp-2 have a protective effect on cerebral ischemia/reperfusion model?

Keywords:

Reperfusion injury, glucagon-like peptide 2, neuroprotective effect, rats,

PDF

___

Siemionow M, Arslan E. Ischemia/reperfusion injury: a review in relation to free tissue transfers. Microsurgery 2004; 24: 468– 475.
Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. P Natl Acad Sci USA 1996; 93: 7911–7916.
Gleeson MH, Bloom SR, Polak JM, Henry K, Dowling RH. Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function. Gut 1971; 12: 773–782.
Kukreja RC, Hess ML. The oxygen free radical system: from equations through membrane-protein interactions to cardiovascular injury and protection. Cardiovasc Res 1992; 26: 641–655.
Power C, Fanning N, Redmond HP. Cellular apoptosis and organ injury in sepsis: a review. Shock 2002; 18: 197–211.
Bremholm L, Hornum M, Henriksen BM, Larsen S, Holst JJ. Glucagon-like peptide-2 increases mesenteric blood flow in humans. Scand J Gastroenterol 2009; 44: 314–319.
Deniz M, Bozkurt A, Kurtel H. Mediators of glucagon-like peptide 2-induced blood flow: responses in different vascular sites. Regul Pept 2007; 142: 7–15.
Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold MJ, Holst JJ, Hadsell D et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006; 130: 150–164.
Bremholm L, Hornum M, Andersen UB, Hartmann B, Holst JJ, Jeppesen PB. The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end- jejunostomy short bowel patients. Regul Pept 2011; 168: 32–38.
Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000; 47: 112–119.
Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009; 58: 1091–1103.
Ivory CP, Wallace LE, McCafferty DM, Sigalet DL. Interleukin- 10-independent anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2008; 295: G1202–1210.
Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, Tanaka H, Sharkey KA. Enteric neural pathways mediate the anti- inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007; 293: G211–221.
Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, Demchyshyn L, Yang ZJ, Kamboj RK, Chen H et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. P Natl Acad Sci USA 1999; 96: 1569–1573.
Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78: 206–209.
Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol 1978; 52: 302–310.
Beutler E. Glutathione. In: Beutler E, editor. Red Blood Cell Metabolism: A Manual of Biochemical Methods. 2nd ed. New York, NY, USA: Grune & Stratton; 1975. pp. 112–114.
Kumral A, Ozer E, Yilmaz O, Akhisaroglu M, Gokmen N, Duman N, Ulukus C, Genc S, Ozkan H. Neuroprotective effect of erythropoietin on hypoxic-ischemic brain injury in neonatal rats. Biol Neonate 2003; 83: 224–228.
Kavakli A, Sahna E, Parlakpinar H, Yahsi S, Ogeturk M, Acet A. The effects of melatonin on focal cerebral ischemia-reperfusion model. Saudi Med J 2004; 25: 1751–1752.
Ban M, Tonai T, Kohno T, Matsumoto K, Horie T, Yamamoto S, Moskowitz MA, Levine L. A flavonoid inhibitor of 5-lipoxygenase inhibits leukotriene production following ischemia in gerbil brain. Stroke 1989; 20: 248–252.
Islekel S, Islekel H, Guner G, Ozdamar N. Alterations in superoxide dismutase, glutathione peroxidase and catalase activities in experimental cerebral ischemia-reperfusion. Res Exp Med (Berl) 1999; 199: 167–176.
Kempski O. Cerebral edema. Semin Nephrol 2001; 21: 303– 307.
Unterberg AW, Stover J, Kress B, Kiening KL. Edema and brain trauma. Neuroscience 2004; 129: 1021–1029.
Candelario-Jalil E, Alvarez D, Merino N, Leon OS. Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils. Neurosci Res 2003; 47: 245–253.
Ozkul A, Akyol A, Yenisey C, Arpaci E, Kiylioglu N, Tataroglu C. Oxidative stress in acute ischemic stroke. J Clin Neurosci 2007; 14: 1062–1066.
Ross D. Glutathione, free radicals and chemotherapeutic agents: mechanisms of free-radical induced toxicity and glutathione-dependent protection. Pharmacol Ther 1988; 37: 231–249.
Comporti M. Glutathione depleting agents and lipid peroxidation. Chem Phys Lipids 1987; 45: 143–169.
Schwenke DC. Antioxidants, dietary fat saturation, lipoprotein oxidation and atherogenesis. Nutrition 1996; 12: 377–379.
Braughler JM, Hall ED. Central nervous system trauma and stroke. I. Biochemical considerations for oxygen radical formation and lipid peroxidation. Free Radic Biol Med 1989; 6: 289–301.
Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991; 11: 81–128.
Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995; 41: 1819–1828.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351–358.
Cirak B, Rousan N, Kocak A, Palaoglu O, Palaoglu S, Kilic K. Melatonin as a free radical scavenger in experimental head trauma. Pediatr Neurosurg 1999; 31: 298–301.
Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136–2142.
Abu-Soud HM, Hazen SL. Nitric oxide modulates the catalytic activity of myeloperoxidase. J Biol Chem 2000; 275: 5425–5430.